Skip to main content


Our Commitment to Privacy

UCB, Inc. (“UCB”) is committed to maintaining the highest level of confidentiality regarding the personal information that we collect, use, maintain, and disclose. This Privacy Policy explains how we handle the personal information you provide to UCB through this Website (“Site”). This Privacy Policy does not apply to UCB websites that do not link to this Privacy Policy, or to third-party websites to which this Site may link. For offline interactions with UCB, this policy supplements (but does not replace) any other policy or notice provided to you as part of your offline interaction(s) with us.

The term “Personal Information” as used throughout this Privacy Policy, applies to any information or set of information collected through the Site that identifies or that is used by or on behalf of UCB to identify you, and includes, for example, medical information. UCB is not a healthcare provider (e.g., a doctor, hospital, pharmacist, etc.) and is generally not subject to the Privacy Rule under the Health Insurance Portability and Accountability Act, commonly known as HIPAA, which imposes additional requirements on healthcare providers relating to protected healthcare information. All capitalized terms used but not defined in this Privacy Policy will have the meanings given to them in the Terms of Use.

Your Consent

Whenever you submit Personal Information to UCB through the Site, you consent to UCB’s collection, use, and disclosure of that Personal Information in accordance with this Privacy Policy. The most current version of this Privacy Policy can always be reviewed by clicking on the “Privacy Policy” hypertext link located at the bottom of the Site.

International users

THE SITE IS INTENDED ONLY FOR USE WITHIN THE U.S. IT IS NOT INTENDED FOR USE OUTSIDE THE U.S. When you provide Personal Information to UCB through the Site, (i) you represent that you are using the Site within the U.S., (ii) you agree to the transfer of any Personal Information that you provide, and (iii) you consent to our use and disclosure of such Personal Information as described in this Privacy Policy.

About children

The Site is not intended for persons under the age of 18. We do not knowingly collect information from any person under the age of 18. If a parent or guardian has reason to believe that a child under the age of 18 has provided us with Personal Information, the parent or guardian should contact us immediately.

Collection of Personal Information

You do not need to provide any Personal Information to visit public sections of the Site. You will be asked to provide us with certain Personal Information to use certain portions of the Site. In the course of requesting such information, we may also ask you to identify your relationship to a particular disease (e.g., as a diagnosed patient, a friend or relative of such a patient, or as a healthcare provider). Your submission of some Personal Information is optional and you can choose not to provide it. Submission of certain Personal Information, however, is required in order for you to participate in certain features or areas of the Site, such as registering as a member; requesting to subscribe to a newsletter; asking a question; or initiating other transactions on the Site. We will inform you on the Site what Personal Information is required and what Personal Information is optional.

UCB may collect Personal Information about health care professionals who register on the Site from public or third party information sources to verify their professional credentials and identity. In some cases, we may augment our existing user databases with information from third parties. Some of this information may be Personal Information, such as change of postal address information and demographic information, which we use to better understand your potential purchasing preferences.

Collection of Non-Personal Information

We also receive and store information that is not personally identifiable to you. This includes, for example, (i) questions, comments, ideas, or suggestions that you provide or other information that we collect that is not linked to any of your Personal Information, (ii) information about your computer collected when you visit the Site, such as your IP address, web browser software (such as Google Chrome), and referring websites, and (iii) the date and time you visited the Site and your online activity within the Site, such as the pages you visited during your use of it (“Non-Personal Information”). One of our goals in collecting automatic Non-Personal Information is to help customize your user experience. If you use a mobile device to access the Site and online resources, we may also collect information about your device, such as your device ID and device type, as well as usage information about your device and your use of our mobile Sites and other mobile resources.

A “cookie” is a small data file that is sent by web servers to your computer’s hard drive, where your web browser files are kept. Cookies enable the Site to store small bits of information on your computer and retrieve that information at a later time. UCB uses two types of cookies: session cookies, which are temporary cookies that are erased from your computer’s memory when you close your web browser or turn your computer off, and persistent cookies, which exist on your computer’s hard drive until they expire, unless you delete them at an earlier time. We use cookies (i) to track your preferences and selections, (ii) to understand general usage of the Site and volume statistical information and improve the content and offerings on the Site, and (iii) to confirm whether you have read or clicked on certain e-mail communications we send to you so that we can make our communications more useful and interesting to you. Cookies and other user tracking mechanisms (e.g., local shared objects), by themselves, do not tell us any of your Personal Information. Once you choose to furnish UCB with Personal Information, however, such Personal Information may be linked to the data stored in the cookie or other tracking mechanism.

Most web browsers permit you to erase cookies from your computer’s hard drive, to block all cookies, or to receive a warning before a cookie is placed on your system. Refer to your web browser instructions or “Help” button to learn more about cookies and the cookie-related options available to you. You should be aware, however, that cookies might be necessary to provide you with certain features available on the Site, such as customized delivery of features and information on products or services.

We may also track your usage of the Site through the use of pixel tags (also called clear .gifs). The information collected through use of pixel tags is not personally identifiable and is considered Non-Personal Information. Collection of Non-Personal Information by Third Parties We may allow third-party advertising companies, including, for example, ad networks, to display advertisements on the Site. These companies may use tracking technologies, such as cookies, to collect anonymous Non-Personal Information about users who view or interact with their advertisements. The Site does not provide any Personal Information to these third parties, but they may collect Non-Personal Information about where you, or others who are using your computer, saw or clicked on the advertisements they deliver, and possibly associate this Non-Personal Information with your subsequent visits to the advertised websites. They may also combine this information with Personal Information they collect from you. This allows them to deliver targeted advertisements and gauge their effectiveness.

Collection of Non-Personal Information by Third Parties

We may allow third-party advertising companies, including, for example, ad networks, to display advertisements on the Site. These companies may use tracking technologies, such as cookies, to collect anonymous Non-Personal Information about users who view or interact with their advertisements. The Site does not provide any Personal Information to these third parties, but they may collect Non-Personal Information about where you, or others who are using your computer, saw or clicked on the advertisements they deliver, and possibly associate this Non-Personal Information with your subsequent visits to the advertised websites. They may also combine this information with Personal Information they collect from you. This allows them to deliver targeted advertisements and gauge their effectiveness.

Use of Personal Information

We may use your Personal Information for the following general purposes:

  • to provide you with the services, products, information, or features you request;
  • to manage your account with us;
  • to respond to your questions and comments;
  • to measure your interest in and improve the content of the Site;
  • to customize the Site to your preferences and selections;
  • to send you information about UCB’s and its partners’ and advertisers’ products or services that may be of interest to you;
  • to solicit information from you, including through surveys;
  • to resolve disputes, troubleshoot problems, or provide you with support in your use of the Site;
  • to audit its online resources for authorized access and security;
  • to enforce the Terms of Use; and
  • for other purposes specified in this Privacy Policy or described to you at the point of collection of your Personal Information.

For information regarding your choices about such uses, please review the “Your choices” section of this Privacy Policy.

Disclosure of information

We may disclose your Personal Information to third parties that agree to protect your Personal Information. In addition, we may disclose your Personal Information in the following circumstances:

  • to third-party vendors we use to support our business (e.g., internet service providers, hosting companies, financial institutions, and companies that provide business analytics, fulfillment services, technical support, and delivery services);
  • to trusted third-party businesses with which we partner to offer you products and services;
  • to any UCB affiliates, subsidiaries, or other related companies;
  • in connection with a corporate transaction, such as the sale, assignment, or other transfer of the business of the Site to which such information relates;
  • in response to subpoenas, court orders, or other legal process;
  • to establish or exercise our legal rights;
  • to defend against legal claims;
  • as required by applicable laws or government regulations;
  • to protect and defend the rights of UCB, the Site, or the users of the Site;
  • under circumstances we believe reasonably necessary to protect the personal safety of users of UCB’s products and services, the Site, or the public; and
  • as is otherwise described in this Privacy Policy or at the point of collection of your Personal Information.

We may also share Non-Personal Information with third parties, including advertisers and investors.

Access and Correction

You can access the Personal Information you have provided to the Site by contacting us. We will take reasonable steps to update or correct Personal Information in our possession that you have submitted via the Site, so long as you notify us of any information that needs to be changed or corrected.

Your choices

You may choose:

  • not to provide Personal Information, but that may result in your inability to obtain certain services or use certain features of the Site;
  • to stop receiving commercial emails from us through the “unsubscribe” or similar hypertext link in any such message we send or by sending an email to the contact email address provided;
  • to delete or decline cookies by changing your browser settings (click “Help” in the toolbar of most browsers for instructions), but if you do so, some of the features and services of the Site may not function properly; or
  • to review and update your Personal Information by contacting us and, if you have an online account on the Site, by logging into that account.


We take reasonable steps to protect your Personal Information as you transmit the information you choose to submit from your computer to our site and to protect such Personal Information from loss, misuse, and unauthorized access, disclosure, alteration, or destruction. You should keep in mind that no internet transmission is ever 100% secure or error free. Therefore, while we take steps to secure your Personal Information, we do not promise, and you should not expect, that your Personal Information will always remain private or free from compromise.

Links to other Websites


Your California Privacy Rights

Subject to certain limits under California Civil Code § 1798.83, California residents may ask UCB to provide them with (i) a list of certain categories of personal information we disclosed to third parties for their direct marketing purposes during the immediately preceding calendar year, and (ii) the identity of those third parties. To make this request, California residents may contact us with the subject line “Request for California Privacy Information.”

Changes to this Privacy Policy

UCB may, from time to time in its sole discretion, change or modify this Privacy Policy. Any changes or modification will be effective upon posting of the revisions on the Site. If UCB makes any changes or modifications to the terms of this Privacy Policy, such new terms will apply to all Personal Information that UCB maintains, including Personal Information that was received before such changes were made. We will notify you about material changes to this Privacy Policy by sending a notice to the email address you provided to us or by placing a prominent notice on the Site. Your access and continued use of the Site constitutes your acceptance of any changes to this Privacy Policy. This Privacy Policy was last updated on February 18, 2016.

Important Safety Information

Warnings and Precautions

  • Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including VIMPAT, increase the risk of suicidal behavior and ideation. Monitor patients taking VIMPAT for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to the healthcare provider.

  • Dizziness and Ataxia: VIMPAT may cause dizziness and ataxia. In adult clinical trials, the onset of dizziness and ataxia was most commonly observed during titration. Advise patients not to drive, operate complex machinery, or engage in other hazardous activities until they are familiar with the effects of VIMPAT on their ability to perform such activities. Dizziness and ataxia were also observed in pediatric clinical trials.

  • Cardiac Rhythm and Conduction Abnormalities

    PR Interval Prolongation, Atrioventricular Block, and Ventricular Tachyarrhythmia
    Dose-dependent prolongations in PR interval with VIMPAT have been observed in clinical studies in adult patients and in healthy volunteers. When VIMPAT is given with other drugs that prolong the PR interval, further PR prolongation is possible.

    In the postmarketing setting, there have been reports of cardiac arrhythmias in patients treated with VIMPAT, including bradycardia, AV block, and ventricular tachyarrhythmia, which have rarely resulted in asystole, cardiac arrest, and death. Most, although not all, cases have occurred in patients with underlying proarrhythmic conditions, or in those taking concomitant medications that affect cardiac conduction or prolong the PR interval. These events have occurred with both oral and intravenous routes of administration and at prescribed doses as well as in the setting of overdose.

    VIMPAT should be used with caution in patients with underlying proarrhythmic conditions such as known cardiac conduction problems (e.g., marked first-degree AV block, second-degree or higher AV block, and sick sinus syndrome without pacemaker), severe cardiac disease (such as myocardial ischemia or heart failure, or structural heart disease), and cardiac sodium channelopathies (e.g., Brugada Syndrome).

    VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state maintenance dose, is recommended. In addition, these patients should be closely monitored if they are administered VIMPAT through the intravenous route. Patients should be made aware of and report cardiac signs or symptoms to their healthcare provider right away.

    Atrial Fibrillation and Atrial Flutter
    VIMPAT administration may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy and/or cardiovascular disease.

  • Syncope: VIMPAT may cause syncope in adult and pediatric patients.

  • Withdrawal of Antiepileptic Drugs: Gradually withdraw VIMPAT (over a minimum of 1 week) to minimize the potential of increased seizure frequency.

  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as multi-organ hypersensitivity, has been reported with antiepileptic drugs, including VIMPAT. Some of these events have been fatal or life-threatening. If signs or symptoms are present, immediately evaluate the patient. Discontinue VIMPAT if an alternative etiology for the signs and symptoms cannot be established.

  • Risks in Patients with Phenylketonuria: VIMPAT oral solution contains aspartame, a source of phenylalanine, which can be harmful in patients with phenylketonuria (PKU). A 200 mg dose of VIMPAT oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Adverse Reactions

  • Adjunctive therapy: In the adult placebo-controlled clinical trials, the most frequently seen adverse reaction with VIMPAT was dizziness (31% vs 8% placebo). Other common adverse reactions occurring in ≥10 percent of VIMPAT-treated patients, and greater than placebo, were headache, nausea, and diplopia.

  • Monotherapy: In the adult clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (occurred at a higher rate of ≥2%).

  • Pediatric patients: Adverse reactions reported in clinical studies of pediatric patients 4 to less than 17 years of age were similar to those seen in adult patients.

  • Injection: In adult adjunctive therapy clinical trials, adverse reactions with intravenous administration generally were similar to those that occurred with the oral formulation, although intravenous administration was associated with local adverse reactions such as injection site pain or discomfort (2.5%), irritation (1%), and erythema (0.5%). When administering a loading dose, the incidence of CNS adverse reactions, such as dizziness, somnolence, and paresthesia, may be higher with 15-minute administration than over a 30- to 60-minute period.

Dosing Considerations

VIMPAT injection is for intravenous and adult use only when oral administration is temporarily not feasible. The loading dose for adult patients should be administered with medical supervision considering the VIMPAT pharmacokinetics and increased incidence of CNS adverse reactions. The safety of VIMPAT injection and the use of a loading dose in pediatric patients have not been studied. Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment. Use in patients with severe hepatic impairment is not recommended. Perform dose titration with caution in all patients with renal and/or hepatic impairment.

VIMPAT is a Schedule V controlled substance.

Please see full Prescribing Information.

For more information on VIMPAT® contact 844-599-CARE (2273).